Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-11-02 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and changes in issued shares, consistent with disclosures of transactions in own shares. There is no indication of it being a full financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains substantive data on share repurchases, not merely an announcement or certification. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2023-11-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2023
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return detailing movements in securities for World Houseware (Holdings) Limited, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The content focuses on share capital and share issuance movements rather than financial performance or earnings. It is a regulatory submission about share capital movements and confirmations, not a financial report or earnings release. The document is about capital changes and share issuance details, fitting the category of Share Issue/Capital Change (SHA). The document length (7,560 characters) is sufficient to be a substantive filing, not just an announcement. Therefore, the classification is SHA with high confidence.
2023-11-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares over multiple dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong (SEHK). The content is a regulatory disclosure of share repurchase activity, not a financial report or earnings release. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure of share repurchase transactions.
2023-11-01 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details numerous repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with listing rules of the Stock Exchange of Hong Kong and confirms that repurchases were made in accordance with these rules. The content is focused on reporting share repurchase transactions and changes in issued share capital, not on financial results, management changes, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2023-10-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details numerous repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. It is a regulatory disclosure about share repurchases and changes in issued share capital, not a financial report, earnings release, or management discussion. The content fits the category of a report on the company's transactions in its own shares (share buybacks). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a formal disclosure report.
2023-10-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details numerous repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with listing rules of the Stock Exchange of Hong Kong (SEHK) and confirms that repurchases were made in accordance with these rules. The content is focused on reporting share repurchase activity and changes in issued shares, not on financial results, management changes, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-10-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.